

Market Round-up

V25 – 16th November, 2018

General Market News:

- MPs in the UK order release of documents on negotiations for **Vertex**' CF drugs
[LINK](#)
- EU expands label of **GSK/Innoviva's** COPD inhaler
[LINK](#)
- US regulators have accepted an application from **AstraZeneca** and **MSD** for use of **Lynparza** as maintenance treatment for patients with newly-diagnosed, BRCA-mutated advanced ovarian cancer.
[LINK](#)
- **Takeda** inches closer to \$62B takeover of **Shire**
[LINK](#)
- **Bristol-Myers Squibb** and **Pfizer** present real-world data for **Eliquis** at American Heart Association meeting
[LINK](#)
- **Novartis** reports positive results from PIONEER-HF trial of **Entresto**
[LINK](#)
- **Pfizer** loses its **Lyrica** drug patent fight in UK Supreme Court
[LINK](#)
- **Samsung Pharmaceutical** fined for \$4 billion accounts breach
[LINK](#)
- Turning words into art: **Merck Serono** launches campaign to bring **MS** insights to life
[LINK](#)

NCPE Drug Updates

- A full pharmacoeconomic assessment is recommended for **Novartis's Lutetium (177Lu) Oxodotreotide (Lutathera®)**
[LINK](#)
- A full pharmacoeconomic assessment is recommended for **Janssen's Abiraterone acetate (Zytiga®)**
[LINK](#)

Biologics / Biosimilars:

- **Pfizer** launches anemia treatment **Retacrit** - its 3rd biosimilar and 2nd in two months at a significant discount to **Amgen's Epogen** and **Johnson & Johnson's Procrit**.
[LINK](#)

Drug Approvals/Filings:

- EU expands label of **GSK/Innoviva's COPD** inhaler
[LINK](#)
- The **FDA** have expanded the use of **MSD's** anti-PD-1 therapy **Keytruda**
[LINK](#)
- **Shire** reports **FDA** accepted filing sNDA for **GATTEX** for children with Short Bowel Syndrome
[LINK](#)
- The **FDA** has accepted a priority review for **AstraZeneca/MSD's Lynparza** in first-line maintenance setting
[LINK](#)
- **NICE** issues final draft guidelines for **Novartis' Kymriah**
[LINK](#)

Brexit:

- UK and EU 'agree text' of draft withdrawal agreement.
[LINK](#)
- The **Brexit Health Alliance (BHA)** has welcomed the agreement on the terms of the UK's withdrawal from the European Union (EU).
[LINK](#)

Further Reading:

- CEO of **Novartis Oncology - Liz Barrett** - recently sat down with Life Science Leader to share some of the formative experiences that shaped her into the leader she has become, including one of the most recent challenges she is embracing at Novartis.
[LINK](#)
 - Efforts to recruit a successor to former **HSE** chief Tony O'Brien have failed, senior health sources have confirmed. John Connaghan, interim director-general of the HSE, has told senior staff that he will remain in the post longer than expected and into 2019 – he did not apply for the permanent job.
[LINK](#)
 - How **Blockchain** will revolutionise the pharmaceutical industry
[LINK](#)
-